Tetramethylscutellarein

Tetramethylscutellarein

SCHEMBL739115

COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)cc3o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 1.00
KMT2A Q03164 4/20 1.00
ALDH1A1 P00352 2/20 1.00
FLT3 P36888 2/20 0.81
ABCB1 P08183 5/20 0.76
ABCG2 Q9UNQ0 2/20 0.76
TP53 P04637 1/20 0.76
MDM2 Q00987 1/20 0.76
CYP1A1 P04798 1/20 0.70
CYP1B1 Q16678 1/20 0.70
POLB P06746 2/20 0.67
MAPT P10636 2/20 0.67
NPC1 O15118 1/20 0.67
KIT P10721 1/20 0.67
NFKB1 P19838 1/20 0.67
OPRD1 P41143 1/20 0.67
RAB9A P51151 1/20 0.67
NFKB2 Q00653 1/20 0.67
RELA Q04206 1/20 0.67
KDM4E B2RXH2 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salvigenin SCHEMBL1427018 0.90 FLT3 (1.00) MEN1KMT2AALDH1A1FLT3ABCB1
SCHEMBL10031424 0.88 FLT3 (0.84) MEN1KMT2AALDH1A1FLT3ABCB1
SCHEMBL6932015 0.88 MEN1 (0.79) MEN1KMT2AALDH1A1FLT3ABCB1
SCHEMBL1976673 0.88 MEN1 (0.79) MEN1KMT2AALDH1A1FLT3ABCB1
SCHEMBL735537 0.88 MAPT (0.85) MEN1KMT2AALDH1A1FLT3ABCB1
SCHEMBL17258307 0.88 MEN1 (0.78) MEN1KMT2AALDH1A1FLT3ABCB1
SCHEMBL30674796 0.88 MEN1 (0.78) MEN1KMT2AALDH1A1FLT3ABCB1
SCHEMBL737068 0.88 MEN1 (0.78) MEN1KMT2AALDH1A1FLT3ABCB1
SCHEMBL9241994 0.87 ALDH1A1 (0.77) MEN1KMT2AALDH1A1FLT3ABCB1
Baicalein Trimethyl Ether SCHEMBL971297 0.87 ABCB1 (0.80) MEN1KMT2AALDH1A1FLT3ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119881142-A Method for screening alpha-glucosidase inhibitor from dried orange peel and application 北京同仁堂股份有限公司 2025-04-25 CN claimed
CN-118376701-B Stomach-invigorating digestion-promoting tablet, detection method of blood-entering components thereof, quality standard of stomach-invigorating digestion-promoting tablet, target analysis method and application 江中药业股份有限公司 2025-04-22 CN claimed
CN-118903051-A Tea polyphenol and caffeine combined polymethoxy flavone preparation and preparation method thereof 华中农业大学 2024-11-08 CN claimed
CN-118376701-A Stomach-invigorating digestion-promoting tablet, detection method of blood-entering components thereof, quality standard of stomach-invigorating digestion-promoting tablet, target analysis method and application 江中药业股份有限公司 2024-07-23 CN claimed
US-20240188613-A1 SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF FIRMENICH INCORPORATED 2024-06-13 US claimed
US-20240090547-A1 SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF FIRMENICH INCORPORATED 2024-03-21 US claimed
US-20240065302-A1 SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF FIRMENICH INCORPORATED 2024-02-29 US claimed
EP-4258896-A1 SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF Firmenich Incorporated (US) 2023-10-18 EP claimed
EP-4258895-A1 SWEETENER COMPOSTIONS COMPRISING SIAMENOSIDE I AND USES THEREOF Firmenich Incorporated (US) 2023-10-18 EP claimed
EP-4258897-A1 SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF Firmenich Incorporated (US) 2023-10-18 EP claimed
EP-1883300-A2 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY Rutgers, The State University of New Jersey (US) 2008-02-06 EP claimed
US-20070088078-A1 Methods for managing adipocyte fat accumulation WELLGEN, INC. 2007-04-19 US claimed
US-7201928-B1 Extracts of orange peel for prevention and treatment of cancer RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-04-10 US claimed
WO-2007024982-A2 METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION WELLGEN, INC. (US) 2007-03-01 WO claimed
US-20070042972-A1 Compositions and methods for optimizing exercise recovery RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-02-22 US claimed
WO-2006127996-A2 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2006-11-30 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042972-A1 Compositions and methods for optimizing exercise recovery GYS1, PYGM, PRDX5 MEN1 4199/4885KMT2A 2147/4885ALDH1A1 3163/4885
US-20070088078-A1 Methods for managing adipocyte fat accumulation FABP4, PLIN5, PLIN3 MEN1 4550/4885KMT2A 1543/4885ALDH1A1 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.